Outside of traditional clinical trials, expanded access is the only legal channel for physicians and their patients to explore unapproved medicine. This webinar explained the regulations and history of FDA-authorized expanded access and reviewed some common misconceptions on the topic. The presenters, Jess Rabourn, CFA (ALS Emergency Treatment Fund) and Dr. Rick Bedlack (Duke University) discussed the opportunity for large scale, centrally coordinated expanded access programs in ALS.
